Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 7:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,094 matching trials from the live ClinicalTrials.gov search.
Conditions
Malignant Melanoma, Squamous Cell Carcinoma of Skin
Interventions
THOR-707, Cemiplimab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation
Interventions
GM-CSF, Rituximab, NK Cell Infusion
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2 (IL-2), ACT with TIL Infusion, Vemurafenib, Lymphodepletion
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Large B-cell Lymphoma, Hodgkin Lymphoma
Interventions
Fludarabine, Cyclophosphamide, CD70.CAR NK Cells, Rimiducid (AP1903)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab, Bendamustine
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
Recruiting No phase listed Observational Accepts healthy volunteers

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

NCT04785989
Conditions
Chronic Lymphocytic Leukemia
Interventions
[U-13C]glucose, [13C5]glutamine
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
Ianalumab, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Farmington Hills, Michigan • Minneapolis, Minnesota • Seattle, Washington
Conditions
Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Mantle Cell Lymphoma (MCL), CNS Lymphoma
Interventions
CD19x22 CAR T Cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
3,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
208
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation
Drug · Radiation · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Conditions
Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
Interventions
Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neuroblastoma
Interventions
131I-MIBG, Vincristine, Irinotecan, Vorinostat
Radiation · Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Conditions
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
Radiation · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
Interventions
Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan)
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 69 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia
Interventions
alemtuzumab, fludarabine phosphate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
Conditions
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
EB103
Biological
Lead sponsor
Estrella Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Sacramento, California • Cleveland, Ohio • Portland, Oregon + 2 more
Conditions
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
Drug
Lead sponsor
Kara Lynn Davis
Other
Eligibility
1 Year to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Conditions
Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions
Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY)
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma
Interventions
filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Interventions
GEN3009, Epcoritamab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Denver, Colorado • Cleveland, Ohio • Columbus, Ohio + 4 more
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, New York
Conditions
Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions
Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell
Drug · Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
3
States / cities
New York, New York • Cincinnati, Ohio • Seattle, Washington